In This Section

Program

Please Note: All session times for the AACR Virtual Meeting: Sarcomas are U.S. Eastern Daylight Time (EDT).

MONDAY, JUNE 28, 2021 

TUESDAY, JUNE 29, 2021 

MondayJune 282021 

Welcome and Keynote Address
11-11:35 a.m.   

Welcome from Cochairs
Elizabeth R. Lawlor, Seattle Children’s Research Institute, Seattle, WA
E. Alejandro Sweet-Cordero, University of California San Francisco, CA
Poul H.B. Sorensen, University of British Columbia, Vancouver, Canada

Keynote Address 
Utilizing underlying tumor biology to guide immunotherapy drug development in sarcoma, one subtype at a time
Sandra D’Angelo, Memorial Sloan Kettering Cancer Center, New York, New York

Break 
11:35-11:45 a.m. 
Plenary Session 1: Model Systems 
Session Chair: Poul H.B. Sorensen, University of British Columbia, Vancouver, Canada
11:45 a.m.-1:10 p.m. 

Patient-derived sarcoma organoids for functional precision medicine applications
Alice Soragni, University California Los Angeles, Los Angeles, California

Zebrafish modeling of fusion-driven rhabdomyosarcoma
Genevieve Kendall, Nationwide Children’s Hospital, Columbus, Ohio

Development of a phenotypically diverse model of soft tissue sarcoma to identify key drivers of sarcoma tumorigenesis
Janai Carr-Ascher, University California Davis, Sacramento, California

Genomics and mouse models of MPNST
Angela Hirbe, Washington University in St. Louis, St. Louis, Missouri

Panel Discussion 

Break  
1:10-1:30 p.m.  
Plenary session 2: Signaling
Session Chair: Elizabeth R. Lawlor, Seattle Children’s Research Institute, Seattle, Washington
1:30–2:55 p.m.   

Targeting fusion dependent molecular pathways in CIC-rearranged sarcoma
Ross Okimoto, University of California San Francisco, San Francisco, California 

Cell cycle dysregulation in GIST
Inga-Marie Schaefer, Brigham and Women’s Hospital, Boston, Massachusetts

Profiling the immunooncology landscape in pediatric osteosarcoma
Troy McEachron, National Institutes of Health, Bethesda, Maryland

An essential requirement for amino acid activation of mTORC1 in PAX3-FOXO1 positive rhabdomyosarcoma
Amit Sabnis, University California San Francisco, San Francisco, California

Panel Discussion

Closing Remarks for the day
Poul H.B. Sorensen, University of British Columbia, Vancouver, Canada
2:55-3 p.m. 

TuesdayJune 29, 2021 

Keynote Address 
11-11:35 a.m.   

Welcome to day 2
Alejandro Sweet-Cordero, University of California San Francisco, California

Keynote Address
Osteosarcoma metastasis: A stereotyped developmental process that creates tumor organs within lungs
Ryan Roberts, Nationwide Children’s Hospital, Columbus, Ohio

Break 
11:35-11:45 a.m. 
Plenary Session 3: Immunotherapy 
Session Chair: E. Alejandro Sweet-Cordero, University of California San Francisco, California
11:45 A.M.-1:10 p.m. 

Unleashing the innate immune system through synergistic targeting of GD2 and CD47 in neuroblastoma and osteosarcoma
Robbie Majzner, Stanford University, Stanford, California

Development of a vaccine to prevent relapse in liposarcoma
Laura Riolobos, University of Washington, Seattle, Washington

Modulating tumor milieu to enhance sarcoma immunotherapy
Alex Huang, Case Western Reserve University, Cleveland, Ohio

Preliminary results of a phase II study of neoadjuvant immune checkpoint blockade for resectable soft tissue sarcoma
Emily Keung, The University of Texas MD Anderson Cancer Center, Houston, Texas

Panel Discussion 

Break  
1:10-1:30 p.m.  
Plenary session 4: Gene Regulation 
Session Chair: Elizabeth R. Lawlor, Seattle Children’s Research Institute, Seattle, Washington
1:30 p.m.–2:55 p.m.  

Ewing sarcoma: An enhancer disease with widespread epigenetic heterogeneity
Eleni Tomazou, St. Anna Children’s Cancer Research Institute (CCRI), Vienna, Austria

Phasing R-loops in and out by FET proteins and their fusions
Jacob Schwartz, University of Arizona, Tucson, Arizona

Epigenetic determinants of tumor heterogeneity in Synovial Sarcoma
Nicolo Riggi, UNIL- Université de Lausanne, Switzerland

When a mutation profoundly alters chromatin dynamics and modulates oncogene regulation
Didier Surdez, Curie Institute, Paris, France

Panel Discussion

Closing Remarks 
Elizabeth R. Lawlor, Seattle Children’s Research Institute, Seattle, Washington
2:55-3 p.m.